Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies

Rituximab seems to be a safe and effective therapy for AIHA in this meta-analysis of observational studies. The authors suggest that it could be used at an earlier point in therapy, before more toxic immunosuppressive drugs, or in place of splenectomy in some cases.